Answers are grounded in this paper and cite their sources.
In this study we prospectively collected data on the use of liraglutide 3 mg in obese Arab patients. As part of routine care, 2092 patients were dispensed liraglutide 3 mg. Median age was 38 years and 77% were women. Median baseline weight was 95 kg and body mass index was 36.6 kg/m 2 . Of the patients, 188 (9%) had previous bariatric surgery. Seven hundred and eighty‐seven patients were treated for ≥16 weeks and their median (interquartile range) weight loss was 6.0 (2.4‐9.4) kg, equivalent to 6.4% (2.6%‐9.7%) of baseline weight ( P < 0.0001, n = 787). Of those treated for ≥16 weeks, 474 (60%) achieved a weight loss of >5% of baseline weight while 182 (23%) achieved >10% weight loss. There was no difference in percentage weight loss between postbariatric surgery (n = 76) and non‐surgical patients (n = 711). As a result of adverse events, mainly gastrointestinal symptoms, 140 (6.7%) of the patients stopped treatment. One patient developed acute pancreatitis in the context of gallstone disease but made an uneventful recovery. Liraglutide 3 mg was well tolerated and resulted in weight loss in routine clinical care similar to that seen in randomized controlled trials.
No takes yet. Share an insight, caveat, or question.
Suliman et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: